Profound Medical (TSE:PRN) Rating Increased to Strong-Buy at Raymond James Financial

Profound Medical (TSE:PRN) was upgraded by investment analysts at Raymond James Financial from a “moderate buy” rating to a “strong-buy” rating in a note issued to investors on Monday,Zacks.com reports.

Profound Medical Trading Up 1.6%

Shares of TSE PRN opened at C$10.44 on Monday. The company’s 50 day simple moving average is C$9.63 and its 200 day simple moving average is C$9.45. Profound Medical has a fifty-two week low of C$5.23 and a fifty-two week high of C$12.40. The firm has a market capitalization of C$379.37 million, a P/E ratio of -8.42 and a beta of 1.26. The company has a debt-to-equity ratio of 12.56, a current ratio of 6.56 and a quick ratio of 14.98.

Profound Medical (TSE:PRN) last announced its quarterly earnings data on Thursday, May 7th. The company reported C$0.26 earnings per share (EPS) for the quarter. Profound Medical had a negative net margin of 206.94% and a negative return on equity of 78.75%. The firm had revenue of C$7.42 million for the quarter. On average, analysts predict that Profound Medical will post -1.9000001 EPS for the current year.

Profound Medical Company Profile

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.